Annual CFI
$96.88 M
-$44.84 M-31.64%
31 December 2023
Summary:
Adverum Biotechnologies annual cash flow from investing activities is currently $96.88 million, with the most recent change of -$44.84 million (-31.64%) on 31 December 2023. During the last 3 years, it has risen by +$377.04 million (+134.58%). ADVM annual CFI is now -31.64% below its all-time high of $141.72 million, reached on 31 December 2022.ADVM Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$13.35 M
-$11.02 M-473.53%
30 September 2024
Summary:
Adverum Biotechnologies quarterly cash flow from investing activities is currently -$13.35 million, with the most recent change of -$11.02 million (-473.53%) on 30 September 2024. Over the past year, it has dropped by -$31.54 million (-173.34%). ADVM quarterly CFI is now -115.82% below its all-time high of $84.38 million, reached on 31 March 2022.ADVM Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$47.58 M
-$31.54 M-196.71%
30 September 2024
Summary:
Adverum Biotechnologies TTM cash flow from investing activities is currently -$47.58 million, with the most recent change of -$31.54 million (-196.71%) on 30 September 2024. Over the past year, it has dropped by -$156.56 million (-143.65%). ADVM TTM CFI is now -129.12% below its all-time high of $163.37 million, reached on 30 September 2022.ADVM TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADVM Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -31.6% | -173.3% | -143.7% |
| 3 y3 years | +134.6% | -227.5% | -171.7% |
| 5 y5 years | +39.5% | +11.1% | -16.5% |
ADVM Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -31.6% | +134.6% | -115.8% | +39.4% | -129.1% | at low |
| 5 y | 5 years | -31.6% | +134.6% | -115.8% | +89.9% | -129.1% | +84.7% |
| alltime | all time | -31.6% | +134.6% | -115.8% | +90.4% | -129.1% | +84.7% |
Adverum Biotechnologies Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$13.35 M(+473.5%) | -$47.58 M(+196.7%) |
| June 2024 | - | -$2.33 M(-89.4%) | -$16.04 M(-130.1%) |
| Mar 2024 | - | -$22.03 M(+123.0%) | $53.31 M(-45.0%) |
| Dec 2023 | $96.88 M(-31.6%) | -$9.88 M(-154.3%) | $96.88 M(-11.1%) |
| Sept 2023 | - | $18.20 M(-72.8%) | $108.99 M(-5.4%) |
| June 2023 | - | $67.02 M(+211.3%) | $115.16 M(+46.0%) |
| Mar 2023 | - | $21.53 M(+863.9%) | $78.87 M(-44.3%) |
| Dec 2022 | $141.72 M(+80.1%) | $2.23 M(-90.8%) | $141.72 M(-13.3%) |
| Sept 2022 | - | $24.37 M(-20.7%) | $163.37 M(+9.3%) |
| June 2022 | - | $30.73 M(-63.6%) | $149.47 M(-4.5%) |
| Mar 2022 | - | $84.38 M(+253.3%) | $156.51 M(+98.9%) |
| Dec 2021 | $78.71 M(-128.1%) | $23.88 M(+128.1%) | $78.71 M(+18.5%) |
| Sept 2021 | - | $10.47 M(-72.3%) | $66.40 M(-186.9%) |
| June 2021 | - | $37.78 M(+474.2%) | -$76.44 M(-62.3%) |
| Mar 2021 | - | $6.58 M(-43.2%) | -$202.84 M(-27.6%) |
| Dec 2020 | -$280.17 M(+311.6%) | $11.58 M(-108.7%) | -$280.17 M(-9.9%) |
| Sept 2020 | - | -$132.37 M(+49.4%) | -$310.95 M(+60.6%) |
| June 2020 | - | -$88.63 M(+25.3%) | -$193.60 M(+36.8%) |
| Mar 2020 | - | -$70.74 M(+268.3%) | -$141.56 M(+108.0%) |
| Dec 2019 | -$68.07 M(-198.0%) | -$19.21 M(+27.9%) | -$68.07 M(+66.7%) |
| Sept 2019 | - | -$15.02 M(-59.0%) | -$40.84 M(+772.2%) |
| June 2019 | - | -$36.59 M(-1433.0%) | -$4.68 M(-110.0%) |
| Mar 2019 | - | $2.75 M(-65.8%) | $46.81 M(-32.6%) |
| Dec 2018 | $69.44 M | $8.03 M(-62.0%) | $69.44 M(-27.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | $21.14 M(+41.9%) | $96.11 M(+23.9%) |
| June 2018 | - | $14.90 M(-41.3%) | $77.59 M(+84.6%) |
| Mar 2018 | - | $25.38 M(-26.8%) | $42.03 M(-134.4%) |
| Dec 2017 | -$122.20 M(-415.2%) | $34.69 M(+1221.6%) | -$122.20 M(-22.6%) |
| Sept 2017 | - | $2.63 M(-112.7%) | -$157.82 M(-1.9%) |
| June 2017 | - | -$20.67 M(-85.1%) | -$160.81 M(+16.8%) |
| Mar 2017 | - | -$138.85 M(>+9900.0%) | -$137.69 M(-455.1%) |
| Dec 2016 | $38.77 M(-193.3%) | -$924.00 K(+155.2%) | $38.77 M(-44.4%) |
| Sept 2016 | - | -$362.00 K(-114.8%) | $69.76 M(-12.2%) |
| June 2016 | - | $2.44 M(-93.5%) | $79.45 M(-6.3%) |
| Mar 2016 | - | $37.62 M(+25.1%) | $84.83 M(-304.1%) |
| Dec 2015 | -$41.57 M(+4308.2%) | $30.06 M(+222.4%) | -$41.57 M(-42.3%) |
| Sept 2015 | - | $9.32 M(+19.1%) | -$72.00 M(-11.6%) |
| June 2015 | - | $7.83 M(-108.8%) | -$81.42 M(-9.2%) |
| Mar 2015 | - | -$88.78 M(>+9900.0%) | -$89.68 M(+9409.8%) |
| Dec 2014 | -$943.00 K(+936.3%) | -$364.00 K(+246.7%) | -$943.00 K(+60.4%) |
| Sept 2014 | - | -$105.00 K(-75.4%) | -$588.00 K(+21.5%) |
| June 2014 | - | -$427.00 K(+808.5%) | -$484.00 K(+706.7%) |
| Mar 2014 | - | -$47.00 K(+422.2%) | -$60.00 K(-34.1%) |
| Dec 2013 | -$91.00 K(+2933.3%) | -$9000.00(+800.0%) | -$91.00 K(+11.0%) |
| Sept 2013 | - | -$1000.00(-66.7%) | -$82.00 K(+1.2%) |
| June 2013 | - | -$3000.00(-96.2%) | -$81.00 K(+3.8%) |
| Mar 2013 | - | -$78.00 K | -$78.00 K |
| Dec 2012 | -$3000.00 | - | - |
FAQ
- What is Adverum Biotechnologies annual cash flow from investing activities?
- What is the all time high annual CFI for Adverum Biotechnologies?
- What is Adverum Biotechnologies annual CFI year-on-year change?
- What is Adverum Biotechnologies quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Adverum Biotechnologies?
- What is Adverum Biotechnologies quarterly CFI year-on-year change?
- What is Adverum Biotechnologies TTM cash flow from investing activities?
- What is the all time high TTM CFI for Adverum Biotechnologies?
- What is Adverum Biotechnologies TTM CFI year-on-year change?
What is Adverum Biotechnologies annual cash flow from investing activities?
The current annual CFI of ADVM is $96.88 M
What is the all time high annual CFI for Adverum Biotechnologies?
Adverum Biotechnologies all-time high annual cash flow from investing activities is $141.72 M
What is Adverum Biotechnologies annual CFI year-on-year change?
Over the past year, ADVM annual cash flow from investing activities has changed by -$44.84 M (-31.64%)
What is Adverum Biotechnologies quarterly cash flow from investing activities?
The current quarterly CFI of ADVM is -$13.35 M
What is the all time high quarterly CFI for Adverum Biotechnologies?
Adverum Biotechnologies all-time high quarterly cash flow from investing activities is $84.38 M
What is Adverum Biotechnologies quarterly CFI year-on-year change?
Over the past year, ADVM quarterly cash flow from investing activities has changed by -$31.54 M (-173.34%)
What is Adverum Biotechnologies TTM cash flow from investing activities?
The current TTM CFI of ADVM is -$47.58 M
What is the all time high TTM CFI for Adverum Biotechnologies?
Adverum Biotechnologies all-time high TTM cash flow from investing activities is $163.37 M
What is Adverum Biotechnologies TTM CFI year-on-year change?
Over the past year, ADVM TTM cash flow from investing activities has changed by -$156.56 M (-143.65%)